![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
SUMMARY
Fluoropyrimidines (5-fluorouracil, capecitabine, S-1, Uftoral® [UFT; Merck, Germany]) and their derivatives are effective in management of colorectal cancer. DPD deficiency is not routinely tested and is usually diagnosed after a patient has severe/grade IV toxicity secondary to the use of 5-fluorouracil or capecitabine. Once DPD deficiency is diagnosed, there are sparse data on the use of UFT or raltitrexed and there are no comparable outcome data with well-known regimens like infusional 5-fluorouracil, leucovorin oxaliplatin (FOLFOX) and infusional 5-fluorouracil, leucovorin, irinotecan (FOLFIRI). Here we report the first case series from India of DPD deficiency and the use of UFT.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.
No writing assistance was utilized in the production of this manuscript.